Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04693624
Other study ID # 18/20/DD-BV
Secondary ID
Status Completed
Phase
First received
Last updated
Start date January 12, 2021
Est. completion date January 31, 2023

Study information

Verified date June 2023
Source M? Ð?c Hospital
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

It has recently been demonstrated that a bolus trigger of hCG induces various unphysiological conditions in the early luteal phase that may negatively affect an IVF treatment cycle's reproductive outcome. The bolus trigger of hCG differ from the natural cycle in mainly three different ways: 1) The timing of the initiation of hCG and progesterone rise is much faster after an hCG trigger than in the natural menstrual cycle 2) the maximal concentrations of hCG and progesterone considerably exceed those naturally observed 3) The timing of the peak progesterone concentration following an hCG trigger is advanced several days compared to the natural cycle. These characteristics may affect the reproductive outcome in treatment cycles but are not explored. The aim of this study is to monitor whether specific trajectories of important luteal phase hormones may predict the chances of conception?


Description:

The early luteal phase after ovarian stimulation and final oocyte maturation using a bolus trigger of hCG is an area that has not received the same attention as regimes and protocols for ovarian stimulation during the follicular phase. The hCG trigger has been considered the golden standard since the beginning of the IVF era almost four decades ago. The hCG trigger serves two main functions: 1) it induces oocytes to advance meiosis to the metaphase of the second meiotic division ready for fertilization and further development, 2) secures stimulation of the corpora lutea to secrete progesterone (P4) during the early luteal phase due to its relatively long half-life. However, recent studies have suggested that each of these two functions may be optimized on their own and that better alternatives to the hCG trigger may be developed including a more physiological trigger for final maturation of follicles and individualized luteal phase support. However, only recently has the early luteal phase after IVF treatment using an hCG bolus trigger been described in studies involving more than just a few patients. These studies suggested that the unphysiological effects of the hCG trigger may be divided into three different categories: 1) The timing of the initiation of hCG and progesterone rise is much faster after an hCG trigger than in the natural menstrual cycle 2) the maximal concentrations of hCG and progesterone considerably exceed those naturally observed 3) The timing of the peak progesterone concentration following an hCG trigger is advanced several days compared to the natural cycle. How each of these effects influences pregnancy outcome in treatment cycles are currently unknown. Further, does characteristics shortly after administration of the hCG trigger for final oocyte maturation subsequently affect the reproductive outcome, and does this provide an opportunity for correcting or improving the luteal phase support given, with the improvement of clinical pregnancy rate as a result is also unknown. The aim of this study is to evaluate the trajectories of four hormones important for corpora lutea function (i.e. P4, 17-OH-P4, hCG, and inhibin-A) during the early luteal phase in women undergoing IVF treatment with luteal phase support given in the form of exogenous P4 administration and evaluate whether clinical pregnancy rates are related to specific characteristics of the early luteal phase. By including the measurements of 17-OH-P4 and inhibin-A the study will obtain an evaluation of the function of corpora lutea itself independent of the P4 administration provided.


Recruitment information / eligibility

Status Completed
Enrollment 95
Est. completion date January 31, 2023
Est. primary completion date August 30, 2022
Accepts healthy volunteers No
Gender Female
Age group 18 Years to 38 Years
Eligibility Inclusion Criteria: - Age 18 - 38 - BMI < 28kg/m2 - Normal ovarian reserve (anti-Müllerian hormone level above 8.93 pmol/L or an antral follicle count of 6 or above within two months prior to stimulation) - Having 4 to 19 follicles with a diameter of 14mm or above on the day of hCG triggering - Receiving a standard GnRH-antagonist protocol for ovarian stimulation - Having indication for fresh embryo transfer - Willingness to participate in the study, and to disclose any medical conditions to the investigator. The patient must be prepared and willing to comply with the requirements of the protocol. - The patient should after appropriate oral and written consent understand the study and be informed that she may withdraw consent at any time without prejudice to future medical care. Exclusion Criteria: - Previous poor ovarian response (= 3 follicles) after appropriate FSH stimulation - Hyper-response defined as =20 follicles =14 mm on the day of trigger - Chronical medical conditions like Diabetes, Crohns disease, Thyroid disease, Hepatitis B, Sexually Transmitted Diseases and simultaneous participation in an interventional clinical trial.

Study Design


Related Conditions & MeSH terms


Intervention

Other:
Hormonal levels
A total of ten (10) blood samples (2ml/each) will be collected during the study for subsequent analysis of progesterone, hCG, inhibin-A, and 17-OH-progesterone: Day of triggering (before the injection of hCG, appx. 6 pm) Twelve (12 hours) after hCG injection (appx. at 6 am) Twenty-four (24) hours after hCG injection (appx. at 6 pm) Thirty-six (36) hours after hCG injection (appx. at 8 am, 2 hours after OPU) One (1) day after OPU (60h after hCG) (appx. at 6 am) Two (2) days after OPU (84h after hCG) (appx. at 6 am) Three (3) days after OPU 108h after hCG) (appx. at 6 am) Four (4) days after OPU (132h after hCG) (appx. at 6 am) Five (5) days after OPU (156h after hCG) (appx. at 6 am) Six (6) days after OPU (180h after hCG) (appx. at 6 am)

Locations

Country Name City State
Vietnam M? Ð?c Hospital Ho Chi Minh City Tan Binh

Sponsors (1)

Lead Sponsor Collaborator
M? Ð?c Hospital

Country where clinical trial is conducted

Vietnam, 

Outcome

Type Measure Description Time frame Safety issue
Primary Live birth rate in relation to the trajectory of progesterone in the early luteal phase Live birth was defined as the birth of at least one newborn after 24 weeks' gestation that exhibited any sign of life (twins were a single count). After 24 weeks of gestation
Primary Live birth rate in relation to the trajectory of 17-OH progesterone in the early luteal phase Live birth was defined as the birth of at least one newborn after 24 weeks' gestation that exhibited any sign of life (twins were a single count). After 24 weeks of gestation
Primary Live birth rate in relation to the trajectory of hCG in the early luteal phase Live birth was defined as the birth of at least one newborn after 24 weeks' gestation that exhibited any sign of life (twins were a single count). After 24 weeks of gestation
Secondary The clinical pregnancy rate in relation to the trajectory of progesterone in the early luteal phase Pregnancy with at least one gestational sac on ultrasound at 7 weeks' gestation with the detection of heart beat activity At 5 weeks after embryo placement
Secondary The ongoing pregnancy rate in relation to the trajectory of progesterone in the early luteal phase Pregnancy with detectable heart rate at 12 weeks' gestation or beyond At 10 weeks or beyond after the embryo placement
Secondary The clinical pregnancy rate in relation to the trajectory of 17-OH progesterone in the early luteal phase Pregnancy with at least one gestational sac on ultrasound at 7 weeks' gestation with the detection of heart beat activity At 5 weeks after embryo placement
Secondary The ongoing pregnancy rate in relation to the trajectory of 17-OH progesterone in the early luteal phase Pregnancy with detectable heart rate at 12 weeks' gestation or beyond At 10 weeks or beyond after the embryo placement
Secondary The miscarriage rate in relation to the trajectory of progesterone in the early luteal phase Pregnancy loss before 12 completed weeks of gestational age Before 12 weeks of gestation
Secondary The miscarriage rate in relation to the trajectory of 17-OH progesterone in the early luteal phase Pregnancy loss before 12 completed weeks of gestational age Before 12 weeks of gestation
Secondary Live birth rate in relation to the trajectory of inhibin A in the early luteal phase Will be reported in a separate paper After 24 weeks of gestation
See also
  Status Clinical Trial Phase
Recruiting NCT02236780 - Influence of Environmental Conditions on In Vitro Fertilization (IVF) Attempts and Induced Pregnancies N/A
Completed NCT06260787 - Clinical Profiles And In Vitro Fertilization Success
Recruiting NCT03400722 - Double Ovarian Stimulation as Accumulation Strategy for Older Infertile Patients With Suboptimal Ovarian Response Phase 4